Graves病即毒性弥漫性甲状腺肿，是一种自身免疫性疾病。Graves眼病是伴有下丘脑-垂体-甲状腺轴功能异常的眼部 病变。其临床特征是以眼球突出、眼睑退缩、上睑迟落为特征性表现，常伴有眼睑水肿、眶周组织浸润、结膜红斑以及视 神经病变等症状。在临床上，Graves眼病具有发病率高、病情进展快、复发率高、治疗方式单一等特点，因此，Graves眼病 成为了临床常见的难治性疾病之一。奎瑜教授认为，Graves眼病归属于中医学“鹘眼凝睛”范畴，认为本病的病位在目，与 肝、脾、肾关系密切，气滞、血瘀、痰凝是疾病发生发展的过程中重要的病理因素。对于 Graves眼病的治疗，奎瑜教授重 视整体及局部相结合的思维，通过灵活运用多种中医外治法，将Graves眼病的治疗路径总结为“一针二刺三耳穴”，应用腹 针、刺络放血、耳穴压豆等多种中医特色外治法进行综合治疗，临床疗效确切，值得总结推广。

Graves’disease，namely toxic diffuse goiter，is an autoimmune disease. Graves’ophthalmopathy is an ocular lesion with hypothalamic-pituitary-thyroid axis dysfunction. Its clinical features are characterized by exophthalmos，eyelid retraction，and delayed upper eyelid. It is often accompanied by eyelid edema，periorbital tissue infiltration， conjunctival erythema， and optic neuropathy. In clinic， Graves’ophthalmopathy has the characteristics of high incidence， rapid progression， high recurrence rate and single treatment. Therefore， Graves’ophthalmopathy has become one of the common refractory diseases in clinic. Professor KUI Yu believes that Graves’ophthalmopathy belongs to the category of‘exophthalmos’in traditional Chinese medicine. He believes that the disease is located in the eye and is closely related to the liver，spleen and kidney. Qi stagnation， blood stasis and phlegm coagulation are important pathological factors in the process of disease occurrence and development. For the treatment of Graves’ophthalmopathy， Professor KUI Yu attaches great importance to the combination of whole and local thinking. Through the flexible use of a variety of external treatment methods of traditional Chinese medicine， the treatment path of Graves’ophthalmopathy is summarized as“abdominal acupuncture， collateral bloodletting and auricular point seed-pressing”. The comprehensive treatment of abdominal acupuncture， collateral bloodletting and auricular point seed-pressing and other external treatment methods with traditional Chinese medicine characteristics has definite clinical efficacy and is worthy of summary and promotion.

R246.9

广东省医学科学技术研究基金资助项目（编号：C2022093）